Your browser doesn't support javascript.
loading
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik, Jiri; Pika, Tomas; Radocha, Jakub; Jungova, Alexandra; Straub, Jan; Jelinek, Tomas; Pour, Ludek; Pavlicek, Petr; Mistrik, Martin; Brozova, Lucie; Krhovska, Petra; Machalkova, Katerina; Jindra, Pavel; Spicka, Ivan; Plonkova, Hana; Stork, Martin; Bacovsky, Jaroslav; Capkova, Lenka; Sykora, Michal; Kessler, Petr; Stejskal, Lukas; Heindorfer, Adriana; Ullrychova, Jana; Skacel, Tomas; Maisnar, Vladimir; Hajek, Roman.
Afiliação
  • Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. abretina@email.cz.
  • Pika T; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
  • Radocha J; 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic.
  • Jungova A; Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic.
  • Straub J; 1st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic.
  • Jelinek T; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
  • Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic.
  • Pavlicek P; Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Mistrik M; Department of Hematology and Transfusiology, Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia.
  • Brozova L; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Krhovska P; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
  • Machalkova K; 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic.
  • Jindra P; Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic.
  • Spicka I; 1st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic.
  • Plonkova H; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
  • Stork M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic.
  • Bacovsky J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
  • Capkova L; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Sykora M; Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
  • Kessler P; Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic.
  • Stejskal L; Department of Hematology, Silesian Hospital in Opava, Opava, Czech Republic.
  • Heindorfer A; Department of Hematology, Hospital Liberec, Liberec, Czech Republic.
  • Ullrychova J; Department of Clinical Hematology, Regional Health Corporation, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic.
  • Skacel T; 1st Department of Medicine, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
  • Maisnar V; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Hajek R; 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic.
BMC Cancer ; 21(1): 73, 2021 Jan 15.
Article em En | MEDLINE | ID: mdl-33451293
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: República Tcheca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: República Tcheca